Medical Cannabis for Gilles de la Tourette Syndrome: An Open-Label Prospective Study

Table 2

Primary outcome efficacy measures (baseline and week 4 and 12 weeks after treatment initiation) for MC treatment.

Rating scale	Baseline		4 weeks^†			12 weeks^‡
	Mean	SD	Mean	SD	Baseline to 4-week change value (Friedman two-way analysis)	Mean	SD	Baseline to 12-week change value (Friedman two-way analysis)
YGTSS-TS	25.3	10.5	17.0	10.7	0.003	16.4	10.1	0.002
YGTSS-I	35.0	11.0	25.0	7.9	0.248	21.0	10.0	0.013
YGTSS-Total	60.3	17.1	42.0	13.3	0.032	37.4	14.6	0.001
PUTS	22.9	5.5	19.4	6.7	0.043	18.3	7.4	0.043
Subjective percentage of tic improvement following treatment	—	—	50.0	23.8	—	53.9	28.8	—

^†, 3 subjects failed to complete midtrial evaluation, 3 subjects terminated the trial prematurely. ^‡; statistically significant. Abbreviations: MC: medical cannabis; YGTSS-TS: Yale Global Tic Severity Scale Tic Score; TGYSS-I: Yale Global Tic Severity Scale Impairment; PUTS: Premonitory Urge for Tic Scale; SD: standard deviation.